Atnaujinkite slapukų nuostatas

El. knyga: Progress in Medicinal Chemistry

Series edited by (WITNET LTD, Cambridge, UK), Series edited by (Professor, University of Sussex, Brighton, UK)
Kitos knygos pagal šią temą:
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Progress in Medicinal Chemistry, Volume 56 provides a review of eclectic developments in medicinal chemistry. This volume includes chapters covering recent advances in cancer therapeutics, fluorine in medicinal chemistry, a perspective on the next generation of antibacterial agents derived by manipulation of natural products, a potential new era for Chagas Disease drug discovery, and imaging in drug development. Specific chapters cover timely topics, such as the development of LRRK2 inhibitors for the treatment of Parkinson's, and recent discoveries and developments in TRPA1 modulators.

Users will find a comprehensive resource on the topic of medicinal chemistry that also discusses avenues for the acceleration of drug discovery programs.

Daugiau informacijos

Contains eclectic developments in medicinal chemistry, with authoritative extended reviews of targets and technologies addressing new therapeutics
Contributors vii
Preface ix
1 Enabling Chemistry Technologies and Parallel Synthesis---Accelerators of Drug Discovery Programmes
1(36)
A. Vasudevan
A.R. Bogdan
H.F. Koolman
Y. Wang
S.W. Djuric
1 Introduction
1(2)
2 The Evolution of Flow-Based Approaches to Synthesis
3(1)
3 Use of High-Temperature Chemistries
3(4)
4 Use of Photochemical and Electrochemical Reactions
7(6)
5 Use of Hazardous Gases (e.g. Diazomethane) in Flow
13(4)
6 Library Design Tools and Processes
17(8)
7 Use of Flow Chemistry for Library Synthesis
25(5)
8 Summary and Future Perspectives
30(7)
Acknowledgements
31(1)
References
31(6)
2 Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease
37(44)
K.V. Christensen
G.P. Smith
D.S. Williamson
1 Introduction
37(1)
2 LRRK2 Biology
38(5)
3 Structural Biology of LRRK2
43(2)
4 Overview of Selective Inhibitors of LRRK2
45(26)
5 Conclusion
71(10)
References
73(8)
3 Recent Progress in the Discovery and Development of TRPA1 Modulators
81(36)
S. Skerratt
1 TRPA1: An Introduction
81(3)
2 Validation as a Target for Drug Discovery
84(7)
3 Medicinal Chemistry and Clinical Status of TRPA1 Modulators
91(13)
4 Recent Structural Insights
104(1)
5 Conclusions and Outlook
105(12)
References
106(11)
4 Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)
117(48)
N.E. Genung
K.M. Guckian
1 Introduction
118(7)
2 Small Molecule IRAK4 Inhibitor Discovery
125(30)
3 Summary of Clinical Status
155(1)
4 Conclusion
156(9)
References
156(9)
Index 165(4)
Cumulative Index of Authors 169(8)
Cumulative Index of Subject 177
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions. Professor Brian Cox is at University of Sussex, Brighton, UK